Article
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2020
Karn T, Denkert C, Weber K E, Holtrich U, Hanusch C, Sinn B V, Higgs B W, Jank P, Sinn H P, Huober J, Becker C, Blohmer J-U, Marmé F, Schmitt W D, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P A, Jackisch C, Untch M, Schneeweiss A, Loibl S
Abstract excerpt
BACKGROUND: The predictive value of tumor mutational burden (TMB), alone or in combination with an immune gene expression profile (GEP), for response to neoadjuvant therapy in early triple negative breast cancer (TNBC) is currently not known, either for immune checkpoint blockade (ICB) or conventional chemotherapy. PATIENTS AND METHODS: We obtained both whole exome sequencing and RNA-Seq data from pretreatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.